INITIATOR PHARMA: Q2 2023 REPORT
Business highlights in Q2 2023In May the Company announced that WHO had selected the International Nonproprietary Name (INN) pudafensine as the official generic name for the company’s patented…
All categories
English
INITIATOR PHARMA: Q1 2023 REPORT
Business highlights in Q1 2023 In March the Company announced the completion of dosing of all 24 patients the the Phase IIa clinical trial with IP2018 and that preliminary results are expected end…
Annual report and Remuneration report 2022 for Initiator Pharma A/S
Initiator Pharma’s Annual Report 2022 and Remuneration Report 2022 has now been published and is available on the company´s home page.